Mobile

A Study of Vedolizumab for Treatment of Graft-Versus-Host Disease (GvHD) that has not responded to steroid treatment in patients who have had stem cell transplantation

Mise à jour : Il y a 4 ans
Référence : EUCTR2016-002985-30

Femme et Homme

  • | Pays :
    • -
  • | Organes :
    • -
  • | Spécialités :
    • -

Extrait

The primary objective is to describe the initial activity, tolerability, and safety and to identify a recommended dose and regimen of vedolizumab IV administered for treatment of steroid-refractory acute intestinal GvHD in patients who have undergone allo-HSCT.

Critère d'inclusion

  • Steroid-Refractory Acute Intestinal Graft-Versus-Host Disease (GvHD)

Liens